대웅제약

069620KOSPI

63.0 / 100

Reference Date: 2026-10-23

Financial Score32.5 / 40

News Sentiment12.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers and ROE significantly exceeds the industry average is also solid. Slightly down 4.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Daewon Pharmaceutical, established in 2002, is a leading pharmaceutical company specializing in the production and sales of specialty drugs and high-purity botulinum toxin 'Nabohta'. In 2025, it achieved sales of 13.91 trillion KRW and operating profit of 2.04 trillion KRW, driven by global market expansion, AI-based digital healthcare solutions, and R&D investments in innovative drugs.

Number of Employees

1,794people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.22Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR

1.06Industry Average 1.204.0Point

In line with industry avg

ROE

18.71Industry Average 8.007.0Point

2.3x industry avg (excellent)

Debt Ratio

56.35Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.8% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 11.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 103,500Won52-week high 194,00052-week low 103,500

1-month return2.0Point

1m -4.34% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0